ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY

Autor: A. V. Jilenko, Dmitry Napalkov, V. A. Sulimov, A. A. Sokolova, O. S. Anikina
Rok vydání: 2015
Předmět:
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty
тромбоэмболические осложнения
medicine.drug_class
новые пероральные антикоагулянты
RM1-950
Dabigatran
novel oral anticoagulants
фибрилляция предсердий
Internal medicine
Antithrombotic
medicine
Diseases of the circulatory (Cardiovascular) system
atrial fibrillation
Pharmacology (medical)
thromboembolic events
Rivaroxaban
business.industry
lcsh:RM1-950
Anticoagulant
Warfarin
Retrospective cohort study
Atrial fibrillation
Vitamin K antagonist
medicine.disease
Surgery
vitamin k antagonists
антагонисты витамина К
lcsh:Therapeutics. Pharmacology
lcsh:RC666-701
RC666-701
Therapeutics. Pharmacology
Cardiology and Cardiovascular Medicine
business
medicine.drug
Zdroj: Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 11, Iss 2, Pp 116-123 (2015)
ISSN: 2225-3653
1819-6446
DOI: 10.20996/1819-6446-2015-11-2-116-123
Popis: Aim. To study the structure and incidence of the in-hospital anticoagulants prescription in patients at high risk of thromboembolic events (TEE) and to evaluate clinical characteristics of anticoagulated patients (by the example of the University Clinical Hospital (UCH) №1 of I.M. Sechenov First Moscow State Medical University (FMSMU).Material and methods. The cross-sectional retrospective study held in UCH №1 of the FMSMU, enrolled 677 patients with atrial fibrillation (AF) for whom the prevention of TEE was indicated.Results. Of 677 analyzed cases (women 70%, men 30%) only 61% of the patients received appropriate anticoagulant therapy. Warfarin was prescribed in 73% of the cases, of them unsatisfactory international normalized ratio (INR) control (time in therapeutic range less than 60%) was revealed in 79%. 8.45% of the vitamin K antagonist treated patients developed hemorrhagic complications. 16% of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4.2% of the dabigatran treated patients and in 14.3% - in case of rivaroxaban therapy.Conclusion. More than a third of non-valvular AF patients receive inadequate antithrombotic therapy in routine clinical practice. 75% of the anticoagulated patients are prescribed the vitamin K antagonists (typically warfarin) as a traditional anticoagulant. At that, only in 21.7% of the patients receiving vitamin K antagonists, this therapy may be considered adequate. Low incidence rate of the novel oral anticoagulants prescription despite the advantages of such treatment also calls attention.
Databáze: OpenAIRE
Externí odkaz: